| Entry |
|
|---|
| Name |
Chlorpropamide (JP18/USP/INN);
Diabinese (TN) |
|---|
| Formula |
C10H13ClN2O3S
|
|---|
| Exact mass |
276.0335
|
|---|
| Mol weight |
276.74
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
|
|---|
| Efficacy |
Antidiabetic, Hypoglycemic, Sulfonylurea receptor agonist |
|---|
| Disease |
Type 2 diabetes mellitus [DS: H00409] |
|---|
| Comment |
Sulfonylurea
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07018 | Sulfonamide derivatives - hypoglycemic agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BB Sulfonylureas
A10BB02 Chlorpropamide
D00271 Chlorpropamide (JP18/USP/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG01508 Sulfonylurea receptor agonist
DG01734 Sulfonylurea
D00271 Chlorpropamide
DG02044 Hypoglycemic agent
DG01734 Sulfonylurea
D00271 Chlorpropamide
Target-based classification of drugs [BR:br08310]
Transporters
ABC transporters
ABCC subfamily
ABCC8(SUR1)/KCNJ11(KIR6.2)
D00271 Chlorpropamide (JP18/USP/INN)
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00271 Chlorpropamide
D00271 Chlorpropamide tablets
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00271
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 17
1 C8x C 20.7200 -8.4700
2 C8y C 20.7200 -9.8700
3 C8x C 21.9324 -10.5700
4 C8x C 23.1449 -9.8700
5 C8y C 23.1449 -8.4700
6 C8x C 21.9324 -7.7700
7 X Cl 19.5076 -10.5700
8 S4a S 24.3824 -7.7700
9 N1b N 25.5949 -8.4700
10 C5a C 26.8073 -7.7700
11 N1b N 28.0197 -8.4700
12 C1b C 29.2322 -7.7700
13 C1b C 30.4446 -8.4700
14 C1a C 31.6570 -7.7700
15 O5a O 26.8073 -6.3700
16 O3c O 23.3925 -6.7801
17 O3c O 25.3724 -6.7801
BOND 17
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 2 7 1
8 5 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 13 14 1
15 10 15 2
16 8 16 2
17 8 17 2
|
|---|
